Pediatric Dosing of Intravenous Sotalol Based on Body Surface Area in Patients with Arrhythmia

被引:0
作者
Xiaomei Li
Yan Zhang
Haiju Liu
He Jiang
Haiyan Ge
Yi Zhang
机构
[1] Tsinghua University,Department of Pediatric Cardiology, Heart Center, The First Hospital of Tsinghua University, School of Clinical Medicine
来源
Pediatric Cardiology | 2017年 / 38卷
关键词
Intravenous sotalol; Tachyarrhythmias; Intravenous dosing; Pediatric dosing;
D O I
暂无
中图分类号
学科分类号
摘要
In a recently published study, we evaluated the efficacy and safety of intravenous sotalol in pediatric patients with incessant tachyarrhythmias and we have found that intravenous sotalol is effective and safe. Our dosing regimen was based on the body weight of the patients. In the US, the recommendation for intravenous sotalol dosing in pediatric patients is based on body surface area (BSA) while taking into consideration the patients’ age. The purpose of this paper is to show the correspondence of a body weight-based dosing regimen when expressed for BSA as mg/m2. We evaluated the similarity of a body weight-based dose to that calculated based on BSA using the US labeling recommendations. Of the 83 patients, 5 were newborns (age: 0–30 days), 39 infants and toddlers (age: 1–24 month), 26 young children (age: >2–6 years), 11 older children (age: 6–12 years), and 2 adolescents (age: 14 years). Each received a loading dose of 1 mg/kg intravenous sotalol administered over 10 min followed by a maintenance dose of 4.5 mg/kg/day. There was a close correlation between the sotalol loading doses calculated based on body weight and BSA across the entire age range (r = 0.977, p < 0.001). In most of the age groups, the body weight-based loading doses were lower or equal to the BSA-based doses. Only in the adolescents were the body weight-based doses higher. The maintenance doses given in our study were significantly higher than the BSA-based dose in newborns: 75 ± 6 versus 53 ± 8 mg/m2, p < 0.05; infants/toddlers: 88 ± 14 versus 77 ± 7 mg/m2, p < 0.001; younger children: 113 ± 12 versus 85 mg/m2, p < 0.001; older children: 123 ± 16 versus 85 mg/m2, p < 0.01; and adolescents 157 ± 30 versus 85.5 mg/m2. Despite the rapid administration of the loading dose and the increased maintenance doses, our body weight-based dosing regimen was safe. Only one newborn had significant adverse event (AV block) that resolved spontaneously after discontinuation of the infusion.
引用
收藏
页码:1450 / 1455
页数:5
相关论文
共 87 条
  • [1] Rao SO(2009)Atrial tachycardias in young adults and adolescents with congenital heart disease: conversion using single dose oral sotalol Int J Cardiol 136 253-257
  • [2] Boramanand NK(2008)Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease Circ J 72 1998-2003
  • [3] Burton DA(2011)High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias Pediatr Cardiol 32 896-903
  • [4] Perry JC(2005)Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia J Am Coll Cardiol 46 1322-1330
  • [5] Miyazaki A(1995)Efficacy and proarrhythmia of oral sotalol in pediatric patients J Am Coll Cardiol 26 1002-1007
  • [6] Ohuchi H(1995)Sotalol for refractory arrhythmias in pediatric and young adult patients: initial efficacy and long-term outcome Am Heart J 130 791-797
  • [7] Kurosaki K(2017)Efficacy of intravenous sotalol for treatment of incessant tachyarrhythmias in children Am J Cardiol 54 86-90
  • [8] Kamakura S(1985)Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial Br Heart J 38 30-32
  • [9] Yagihara T(1999)Hemodynamic effects and electrophysiological effects of sotalol to patients with fatal ventricular arrhythmia Chin J Inter Med 36 1-9
  • [10] Yamada O(2000)A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation Ann Emerg Med 81 1450-1454